XCancer

Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).

Description:

Study in children and adolescents of 177Lu DOTATATE (Lutathera®) combined with the PARP inhibitor olaparib for treatment of recurrent or relapsed solid tumours expressing somatostatin receptors (SSTR) (LuPARPed)

Sponsor:

Fundación de investigación HM

Phase:

Phase 1/2

Contacts:

Marta Osuna Marco MD, Medical Degree (CONTACT)

marta.osuna@startmadrid.com

+34 917 08 99 35

Marta Osuna Marco, PhD (STUDY_DIRECTOR)

START Pediatrics (CONTACT)

pediatrics@startresearch.com

Government Study Link:

NCT06607692 - Click here to see study on

ClinicalTrials.gov

Inclusion
  • Score = 1: Above blood pool and lower than liver
  • Score = 0: Below or equal to blood pool
  • ≥ 3 years at the moment of inclusion in the trial.
  • Diagnosis: relapsed/refractory solid tumours with positive uptake on SSTR-PET (PET-CT or PET-MRI), performed in the previous three months before entering the study.The evaluation of SSTR expression will be classified according to a qualitative 4-point scale: SSTR expression V (visual score):
  • * 18 months - 18 years of age at the time of the initial diagnosis.
Exclusion

Exclusion Criteria Not Yet Provided